{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:09:35Z","timestamp":1790712575844,"version":"4.1.0"},"reference-count":29,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHSN272201000038I"],"award-info":[{"award-number":["HHSN272201000038I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["HHS272201100018I"],"award-info":[{"award-number":["HHS272201100018I"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI101497"],"award-info":[{"award-number":["AI101497"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Coccidioidal meningitis can cause significant morbidity, and lifelong antifungal therapy is often required. VT-1598 is a fungus-specific Cyp51 inhibitor that has potent\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity against\n                    <jats:named-content content-type=\"genus-species\">Coccidioides<\/jats:named-content>\n                    species. We evaluated the\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy of VT-1598 in murine models of central nervous system coccidioidomycosis caused by\n                    <jats:named-content content-type=\"genus-species\">C. posadasii<\/jats:named-content>\n                    and\n                    <jats:named-content content-type=\"genus-species\">C. immitis<\/jats:named-content>\n                    . Infection was introduced via intracranial inoculation, and therapy began 48 h postinoculation. Oral treatments consisted of vehicle control, VT-1598, and positive controls of fluconazole in the\n                    <jats:named-content content-type=\"genus-species\">C. immitis<\/jats:named-content>\n                    study and VT-1161 in the\n                    <jats:named-content content-type=\"genus-species\">C. posadasii<\/jats:named-content>\n                    study. Treatment continued for 7 and 14 days in the fungal-burden and survival studies, respectively. Fungal burden was assessed in brain tissue collected 24 to 48 h posttreatment in the fungal-burden studies, on the days the mice succumbed to infection, or at prespecified endpoints in the survival studies. VT-1598 plasma concentrations were also measured in the\n                    <jats:named-content content-type=\"genus-species\">C. posadasii<\/jats:named-content>\n                    study. VT-1598 resulted in significant improvements in survival in mice infected with either species. In addition, the fungal burden was significantly reduced in the fungal-burden studies. Plasma concentrations 48 h after dosing stopped remained above the VT-1598 MIC against the\n                    <jats:named-content content-type=\"genus-species\">C. posadasii<\/jats:named-content>\n                    isolate, although levels were undetectable in the survival study after a 4-week washout. Whereas fungal burden remained suppressed after a 2-week washout in the\n                    <jats:named-content content-type=\"genus-species\">C. immitis<\/jats:named-content>\n                    model, a higher fungal burden was observed in the survival arm of the\n                    <jats:named-content content-type=\"genus-species\">C. posadasii<\/jats:named-content>\n                    model. This\n                    <jats:italic>in vivo<\/jats:italic>\n                    efficacy supports human studies to establish the utility of VT-1598 for the treatment of coccidioidomycosis.\n                  <\/jats:p>","DOI":"10.1128\/aac.02258-17","type":"journal-article","created":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T09:02:47Z","timestamp":1517389367000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":49,"title":["The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis"],"prefix":"10.1128","volume":"62","author":[{"given":"Nathan P.","family":"Wiederhold","sequence":"first","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa F.","family":"Shubitz","sequence":"additional","affiliation":[{"name":"Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura K.","family":"Najvar","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Jaramillo","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Olivo","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Catano","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hien T.","family":"Trinh","sequence":"additional","affiliation":[{"name":"Valley Fever Center for Excellence, University of Arizona, Tucson, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Yates","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schotzinger","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Garvey","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas F.","family":"Patterson","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"},{"name":"South Texas Veterans Health Care System, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2307\/3761847"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S34434"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2006.03.033"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2015.10.008"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1982.00340160069017"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw086"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw360"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02634-16"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11046-007-9018-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.06.037"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068"},{"key":"e_1_3_2_13_2","volume-title":"ASM Microbe","author":"Wiederhold NP","year":"2017","unstructured":"Wiederhold NP, Tran BH, Patterson H, Yates CM, Schotzinger RJ, Garvey EP. 2017. The novel fungal Cyp51 inhibitor VT-1598 demonstrates potent in vitro activity against endemic fungi, Aspergillus, and Rhizopus, abstr. ASM Microbe, New Orleans, LA, 1 to 5 June."},{"key":"e_1_3_2_14_2","first-page":"78","article-title":"The treatment of coccidioidal meningitis: the use of amphotericin B in a group of 25 patients","volume":"101","author":"Winn WA","year":"1964","unstructured":"Winn WA. 1964. The treatment of coccidioidal meningitis: the use of amphotericin B in a group of 25 patients. Calif Med 101:78\u201389.","journal-title":"Calif Med"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/clind\/16.2.247"},{"key":"e_1_3_2_16_2","first-page":"339","article-title":"Coccidioidal meningitis: the use of amphotericin B in treatment","volume":"94","author":"Einstein HE","year":"1961","unstructured":"Einstein HE, Holeman CW, Jr, Sandidge LL, Holden DH. 1961. Coccidioidal meningitis: the use of amphotericin B in treatment. Calif Med 94:339\u2013343.","journal-title":"Calif Med"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3181f378a8"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-124-3-199602010-00004"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199105000-00016"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/524669"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis437"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00626-12"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.12834"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01558-13"},{"key":"e_1_3_2_25_2","volume-title":"Product information: Sporanox oral capsules","author":"Janssen Pharmaceuticals","year":"2017","unstructured":"Janssen Pharmaceuticals. 2017. Product information: Sporanox oral capsules. Janssen Pharmaceuticals, Inc., Titusville, NJ."},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00593-15"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.6.1132"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701288070"},{"key":"e_1_3_2_29_2","volume-title":"Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.4.587"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02258-17","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02258-17","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:07:46Z","timestamp":1645459666000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02258-17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1128\/AAC.02258-17"],"URL":"https:\/\/doi.org\/10.1128\/aac.02258-17","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"2017-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02258-17"}}